Skip to main content

Table 1 Baseline demographic and clinical characteristics of the entire study population

From: Biomarkers of pulmonary hypertension in patients with scleroderma: a case–control study

  Pulmonary hypertension (n = 37) Controls (n = 40) p value
Sex, n (%)    1.00
 Male 3 (8.1) 4 (10.0)
 Female 34 (91.9) 36 (90.0)
Mean age at last sample, yr (range) 64.9 (38–89) 55.9 (27–73) <0.01
Race, n (%)    0.03
 White 30 (81.1) 39 (97.5)
 African American 7 (18.9) 1 (2.5)
Median disease duration, yr (IQR)a 10.7 (1.4–16.0) 8.2 (3.8–9.7) <0.01
Limited SSc, n (%) 31 (83.8) 26 (65) 0.06
Ever smoker, n (%) 12 (32.4) 15 (37.5) 0.64
Median modified Rodnan skin score (0–51) (IQR) 7.0 (5.0–15.0) 7.0 (4.5–18.0) 0.97
Severe Raynaud’s symptoms, n (%)b 29 (78) 16 (40) <0.01
FVC, mean±SD 67.5±21.2 88.1±15.9 <0.01
DLCO, mean±SD 48.4±18.9 (n = 36) 92.1±24.0 <0.01
Median RVSP (IQR) 60 (48–74.5) (n = 36) 33 (27–36) (n = 25) <0.01
Anti-Scl-70, n (%) 5 (13.5) 7 (17.5) 0.63
Anti-RNP, n (%) 4 (11.4) (4/35) 2 (5.9) (2/34) 0.67
Anti-centromere, n (%) 17 (46.0) 13 (32.5) 0.23
  1. Abbreviations: DLCO diffusing capacity of carbon monoxide, FVC forced vital capacity, IQR interquartile range, RNP ribonucleoprotein, RVSP right ventricular systolic pressure, Scl-70 topoisomerase-1, SD standard deviation, SSc scleroderma
  2. Non-parametric continuous data were evaluated using the Wilcoxon-Mann–Whitney test and are represented as median (IQR)
  3. aFrom time of Raynaud’s onset
  4. bBased on Medsger severity score (Medsger score >1 = severe Raynaud’s)